Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Abstract

In the treatment of patients with Parkinson's disease, apomorphine has an established place as a back-up therapy if other antiparkinsonian drugs, such as levodopa and oral dopamine agonists, have not controlled the existing response fluctuations. Apomorphine is a synthetic derivative of morphine, with a totally distinct pharmacological profile. It is a very lipophilic compound which is easily (auto)oxidised. This (auto)oxidation is the main metabolic route besides glucuronidation and sulphation, which are both responsible for about 10% of the metabolic transformation. Apomorphine quickly passes the nasal and intestinal mucosa as well as the blood-brain barrier (depending on the administration route). Many routes of administration have been explored, but subcutaneous, sublingual, nasal and rectal administration are used in clinical practice. The volume of distribution varies between 1 and 2 times bodyweight. The elimination half-life is very short (30 to 90 min) depending on the type of parenteral administration. Apomorphine is a high clearance drug (3 to 5 L/kg/h) and is mainly excreted and metabolised by the liver. Only 3 to 4% is excreted unchanged in the urine. The clinical effect of apomorphine can be linked directly to its concentration in the cerebrospinal fluid. Consequently, a 2-compartment model can be used to predict the clinical effects of apomorphine. The pharmacokinetic-pharmacodynamic data reflect the clinical observations of steep dose-effect curves if apomorphine is used in patients with random 'on-off' fluctuations. These dose-effect curves are less steep in stable or 'wearing-off' (end-of-dose deterioration) patients. Intravenous infusions of apomorphine in combination with timed motor assessments can be used clinically to characterise the therapeutic window of a particular patient if dyskinesia persists after single injections of apomorphine. If more population data become available, the population pharmacokinetics-pharmacodynamics of apomorphine could be helpful in predicting the clinical effects of apomorphine in the several subgroups of patients with Parkinson's disease.

• Authors: C Neef, T van Laar
• Journal: Clinical pharmacokinetics (Clin Pharmacokinet) Vol. 37 Issue 3 Pg. 257-71 (Sep 1999) ISSN: 0312-5963 [Print] Switzerland
• PMID: 10511920 (Publication Type: Journal Article, Review)

Chemical References

• Antiparkinson Agents
• Levodopa
• Apomorphine

Topics

• Antiparkinson Agents (administration & dosage, adverse effects, pharmacokinetics, pharmacology)
• Apomorphine (administration & dosage, adverse effects, pharmacokinetics, pharmacology)
• Dose-Response Relationship, Drug
• Drug Interactions
• Humans
• Levodopa (pharmacokinetics, pharmacology)
• Parkinson Disease (metabolism)
• Time Factors